ASCO Annual Meeting

Patients Should Ask Their Providers About Clinical Trial Results

July 7th 2021

Results demonstrating the efficacy of Bavencio highlight the importance of incorporating recent clinical trial successes into the treatment conversation.

New Potential Immunotherapy Treatment Options in Advanced Esophageal Squamous Cell Carcinoma

June 28th 2021

Opdivo was the first PD-1 inhibitor to show durable responses in patients with esophageal squamous cell carcinoma.

Novel 4-Drug Combo Significantly Improves Treatment Responses in Group of Patients with Breast Cancer

June 15th 2021

Treatment with pyrotinib and the chemotherapies trastuzumab, docetaxel and carboplatin significantly improved response rates over the triplet chemotherapy regimen alone in the neoadjuvant treatment of patients with HER2-positive breast cancer.

Trodelvy Associated with Better Benefits Than Chemo in Metastatic Triple-Negative Breast Cancer, Regardless of Agent

June 9th 2021

The data, according to the study’s lead author, confirm that Trodelvy should be considered a new standard of care in patients with metastatic triple-negative breast cancer.

Patients with Early Triple-Negative Breast Cancer May Benefit from Imfinzi-Neoadjuvant Chemo Combo

June 8th 2021

Patients with early triple-negative breast cancer receiving Imfinzi in addition to neoadjuvant chemotherapy saw increased survival rates and complete responses to treatment.

Novel Therapy Appears Safe in Certain Patients with Prostate Cancer

June 7th 2021

The treatment was also associated with antitumor activity in patients with metastatic castration-resistant prostate cancer.

Novel Therapy Shows Promise in Group of Patients with Metastatic Colon Cancer

June 7th 2021

Responses to the study drug, according to one of the study’s authors, appeared far superior than what would have been expected with other treatments in patients with HER2-expressing metastatic colorectal cancer.

Imfinzi May Contribute to Long-Term Survival Improvements in Unresectable Non-Small Cell Lung Cancer

June 7th 2021

The long-term follow-up data, according to one of the study’s authors from the Sarah Cannon Cancer Institute, demonstrate “a new benchmark for the standard of care” in the treatment of patients with unresectable stage 3 non-small cell lung cancer.

Aumolertinib Improves Survival in Advanced Non-Small Cell Lung Cancer

June 7th 2021

Treatment with aumolertinib was associated with prolonged survival in patients with advanced non-small cell lung cancer.

Abecma Continues to Improve Survival in Heavily Pretreated Patients With Multiple Myeloma

June 6th 2021

After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.

Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer

June 6th 2021

Previously treated patients with non-small cell lung cancer tended to have better responses with Retevmo than they did with prior treatments.

Novel Combo Therapy Shows Promise in Certain Patients With Non-Hodgkin Lymphoma

June 6th 2021

Treatment with a novel combination therapy was associated with increased efficacy among patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma and was also well tolerated.

‘Incredible’ That a One-Time Infusion of CAR-T Cell Therapy Induces Durable Responses in Acute Lymphoblastic Leukemia

June 6th 2021

Although recent data show how promising a single-infusion of a specific CAR-T cell therapy may be for patients with acute lymphoblastic leukemia, an expert from the Moffitt Cancer Center notes that more research is needed for those deemed too ill to receive the treatment.

Lenvima-Keytruda Combination May Show ‘Promising Antitumor Activity’ in Advanced Colorectal Cancer

June 6th 2021

More than half of patients with previously treated advanced colorectal cancer who were treated with Lenvima and Keytruda were alive at six months while maintaining a manageable safety profile.

Certain Patients with Prostate Cancer Continue to Tolerate Extended Nubeqa Treatment

June 6th 2021

Patients with nonmetastatic castration-resistant prostate cancer continued to tolerate long-term treatment with Nubeqa, allowing them to maintain their quality of life and remain on therapy.

Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients with Multiple Myeloma

June 5th 2021

A single infusion of a novel CAR-T cell therapy was associated with early and deep responses to treatment among a certain group of patients with multiple myeloma.

Gavreto ‘Very Well Tolerated’ in RET Fusion-Positive Non-Small Cell Lung Cancer

June 5th 2021

Findings demonstrated that Gavreto could clinically benefit those with RET fusion-positive non-small cell lung cancer, including those who are treatment naïve.

Zejula May Improve Survival in Certain Ovarian Cancer Subgroups

June 5th 2021

Progression-free survival improved with Zejula compared with placebo in patients with BRCA-mutated ovarian cancer with no new safety signals.

Men of African Ancestry Less Likely to Receive Genomic Profiling Early During Prostate Cancer Treatment

June 5th 2021

The data, according to one of the study’s authors, are critical in understanding the disparities in prostate cancer.

Opdivo Combined with Yervoy or Chemo Improves Survival in Unresectable and Advanced Esophageal Cancer

June 5th 2021

Adding Opdivo to treatment with Yervoy or chemotherapy improved survival, compared with chemotherapy alone in patients with unresectable and advanced esophageal cancer.

Lynparza Following Standard of Care Treatments Effective in Some Patients with High-Risk Breast Cancer

June 5th 2021

Some patients with early HER2-negative breast cancer at high risk for disease recurrence achieved meaningful benefit with Lynparza after receiving standard of care therapies, such as surgery or chemotherapy.

Novel Drug-Chemo Combo Significantly Improves Survival in Rare Form of Head and Neck Cancer

June 5th 2021

The addition of a novel drug to the chemotherapies gemcitabine and cisplatin significantly improved a survival outcome in patients with a rare form of head and neck cancer, compared with chemotherapy alone.

Addition of Chemo After Chemoradiation Fails to Improve Survival in Locally Advanced Cervical Cancer

June 4th 2021

Treatment with chemotherapy following the standard chemoradiation treatment failed to improve multiple survival outcomes in women with locally advanced cervical cancer.

Investigational Therapy Significantly Improves Survival in Patients with Prostate Cancer

June 4th 2021

The addition of an investigational therapy to standard-of-care treatment was associated with a median overall survival of 15.3 months in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

Increased Screening Associated with Improved Outcomes in Younger Black Patients with Prostate Cancer

May 21st 2021

The study results lend strength to discuss prostate cancer screening in younger Black men, according to an expert.

Tecentriq Significantly Improves Survival Outcome in Patients with Early-Stage Non-Small Cell Lung Cancer

May 21st 2021

The data, according to an expert, show that treatment with Tecentriq could delay disease progression to an advanced stage, as well as the need for more aggressive therapy.

‘Great Deal of Work’ Still Needed to Reverse Increasing Rates of Several HPV-Related Cancers

May 20th 2021

Almost 20 years of data indicate that the incidence of HPV-related cervical cancer is noticeably declining, however other cancers related to the virus continue, and are expected, to increase.

Long-Term Cancer Survival May Be Worse in States With Lower Medicaid Eligibility Limits

May 19th 2021

Survival rates in this study were similar across cancer types including colorectal and prostate cancers, which may indicate a need for updated policies to include more patients.

Newly Diagnosed? One Cancer Expert Offers Her Advice

August 5th 2019

The executive director of the Cancer Policy Institute at the Cancer Support Community offers some candid advice for individuals who may be facing a new cancer diagnosis.

Merger of Two Groups Boosts Psychosocial Support Resources for Patients With Cancer

July 29th 2019

The merging of with Cancer Support Community facilitates more comprehensive social and emotional support for patients and caregivers affected by cancer.